Who is sponsoring NCT03985670?

NCT03985670 is sponsored by Henan Cancer Hospital.

What drugs are being tested in NCT03985670?

Interventions in NCT03985670: teripalimab plus chemotherapy, chemotherapy plus teripalimab.

What condition does NCT03985670 study?

NCT03985670 studies Squamous Cell Carcinoma, Esophageal Cancer, Perioperative Period.

Is NCT03985670 still recruiting?

NCT03985670 is currently status unknown. Last updated 12 December 2019.

Last reviewed 2019-12-12 · How we verify

NCT03985670

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer

Status unknown Phase 2 Last updated 12 December 2019

What this trial tests

Phase 2 trial testing teripalimab plus chemotherapy in Squamous Cell Carcinoma in 30 participants. Status unknown.

Timeline

10 July 2019

Primary endpoint
30 April 2021

30 April 2023

Quick facts

Lead sponsor	Henan Cancer Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	10 July 2019
Primary completion	30 April 2021
Estimated completion	30 April 2023
Sites	1 location across China

Drugs / interventions tested

teripalimab plus chemotherapy — full drug profile →
chemotherapy plus teripalimab — full drug profile →

Conditions studied

Squamous Cell Carcinoma — all drugs for Squamous Cell Carcinoma →
Esophageal Cancer — all drugs for Esophageal Cancer →
Perioperative Period — all drugs for Perioperative Period →

Sponsor

Henan Cancer Hospital

Who can join

Adults 18 to 70, any sex, with Squamous Cell Carcinoma or Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The prognosis of locally advanced esophageal squamous cell carcinoma is poor,the role of chemotherapy as neoadjuvant therapy in locally advanced esophageal cancer has been established, which can convert some unresectable esophageal cancer into resectable esophageal cancer.PD-1 antibody has been shown to improve the pathological complete response rate in NSCLC, however, the data in neoadjuvant of esophageal squamous carcinoma is relatively rare. This study was designed to know the value of PD-1 antibody in neoadjuvant therapy of esophageal cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade.
Yang J, Liu X, Cao S, Dong X, et al · · 2020 · cited 134× · PMID 33014854 · DOI 10.3389/fonc.2020.01727
Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis.
Ge F, Huo Z, Cai X, Hu Q, et al · · 2022 · cited 94× · PMID 36322089 · DOI 10.1001/jamanetworkopen.2022.39778
The Sequence of Chemotherapy and Toripalimab Might Influence the Efficacy of Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Cancer-A Phase II Study.
Xing W, Zhao L, Zheng Y, Liu B, et al · · 2021 · cited 67× · PMID 34938292 · DOI 10.3389/fimmu.2021.772450
Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Wang R, Liu S, Chen B, Xi M. · · 2022 · cited 35× · PMID 36291954 · DOI 10.3390/cancers14205168
The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer.
Yang H, Wang K, Wang T, Li M, et al · · 2020 · cited 35× · PMID 32195194 · DOI 10.3389/fonc.2020.00300
Immunotherapy for Esophageal Cancer: State-of-the Art in 2021.
Teixeira Farinha H, Digklia A, Schizas D, Demartines N, et al · · 2022 · cited 33× · PMID 35158822 · DOI 10.3390/cancers14030554
A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909).
Zheng Y, Liu XB, Sun HB, Xu J, et al · · 2021 · cited 33× · PMID 33553366 · DOI 10.21037/atm-20-5404
Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis.
Liu Y, Bao Y, Yang X, Sun S, et al · · 2023 · cited 24× · PMID 36761760 · DOI 10.3389/fimmu.2023.1117448

Verify or expand the search:

Other recruiting trials for Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07223424 — Patient Preference for Subcutaneous vs. Intravenous Immune Therapy · Phase 2 · recruiting
NCT07095608 — Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain · NA · recruiting
NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies · recruiting

Other Henan Cancer Hospital trials

Trials by the same sponsor.

NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03985670 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
Last refreshed: 12 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03985670.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing